Translational and Clinical Pharmacology

Scope & Guideline

Connecting Science and Practice in Pharmacology

Introduction

Immerse yourself in the scholarly insights of Translational and Clinical Pharmacology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2289-0882
PublisherKSCPT
Support Open AccessNo
CountrySouth Korea
TypeJournal
Convergefrom 2014 to 2024
AbbreviationTRANSL CLIN PHARMACO / Transl. Clin. Pharmacol.
Frequency-
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressKPX Bld. 15F, mapodaero 137, mapo-gu, SEOUL 0000, SOUTH KOREA

Aims and Scopes

Translational and Clinical Pharmacology aims to bridge the gap between laboratory research and clinical applications, focusing on the pharmacological aspects of drug development and therapeutic interventions. The journal emphasizes innovative methodologies and approaches to improve drug efficacy, safety, and regulatory compliance.
  1. Pharmacokinetics and Drug Interactions:
    A core focus of the journal is on the pharmacokinetics of various drugs, including studies on bioequivalence, drug-drug interactions, and the effects of food on drug absorption. This area is critical for optimizing dosing regimens and ensuring patient safety.
  2. Clinical Trial Methodologies:
    The journal publishes articles on advanced clinical trial designs, including adaptive trials and the incorporation of real-world data. This scope is vital for enhancing the efficiency and relevance of clinical research.
  3. Emerging Therapies and Treatment Modalities:
    Research on novel therapeutic agents and treatment strategies, including pharmacogenomics and innovative drug formulations, is frequently highlighted, reflecting the journal's commitment to advancing therapeutic options.
  4. Regulatory Science and Innovation:
    The journal emphasizes the importance of regulatory frameworks in drug development, discussing innovations in regulatory practices and guidelines that facilitate the approval and monitoring of new therapies.
  5. Patient-Centric Research:
    An increasing emphasis is placed on studies that consider patient perspectives, outcomes, and real-world evidence, aligning with trends toward personalized medicine and patient-centered care.
Recent publications in Translational and Clinical Pharmacology reveal several emerging themes that are gaining traction. These trends reflect the evolving landscape of pharmacological research and the integration of new technologies and methodologies.
  1. Integration of Data Science and AI:
    There is a growing trend towards utilizing data science and artificial intelligence, such as machine learning and natural language processing, to enhance drug development processes and clinical trial efficiency. This reflects the increasing importance of computational methods in pharmacology.
  2. Decentralized Clinical Trials (DCTs):
    The focus on decentralized clinical trials has emerged prominently, influenced by the need for flexible and adaptive trial designs that can accommodate diverse patient populations and improve access to clinical research.
  3. Personalized and Precision Medicine:
    Research on personalized medicine, including pharmacogenomics and tailored therapeutic approaches, is increasingly emphasized. This trend aligns with the broader movement towards individualized treatment strategies based on genetic and phenotypic characteristics.
  4. Therapeutic Innovations in Mental Health:
    There is an upward trend in exploring new therapies for mental health conditions, reflecting growing recognition of mental health issues and the need for effective treatment options.
  5. Real-World Evidence and Outcomes Research:
    The integration of real-world evidence into clinical research is becoming increasingly relevant, as studies begin to focus on outcomes that matter to patients in everyday settings, beyond controlled clinical trial environments.

Declining or Waning

While Translational and Clinical Pharmacology continues to explore a broad range of topics, certain themes appear to be diminishing in focus over recent years. These waning scopes may reflect shifts in research priorities or advancements in methodologies.
  1. Traditional Pharmacology Studies:
    There seems to be a decline in purely traditional pharmacology studies that do not incorporate modern methodologies such as pharmacogenomics or machine learning. This shift indicates a move towards more integrative and advanced approaches in pharmacological research.
  2. Case Reports and Isolated Clinical Observations:
    The publication of single case reports and isolated clinical observations appears to be decreasing. This trend may reflect a preference for larger studies that provide more generalizable data and insights.
  3. Basic Laboratory Research:
    There is a noticeable reduction in articles focusing solely on basic laboratory research without direct translational implications. The journal seems to be prioritizing studies that have clear clinical applications or implications for human health.

Similar Journals

Expert Opinion on Drug Metabolism & Toxicology

Uncovering the Science Behind Drug Metabolism
Publisher: TAYLOR & FRANCIS LTDISSN: 1742-5255Frequency: 12 issues/year

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Elevating the standards of pharmacological research and clinical application.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Drug Discoveries and Therapeutics

Fueling the quest for effective medical solutions.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

CPT-Pharmacometrics & Systems Pharmacology

Exploring the future of drug development and patient safety.
Publisher: WILEYISSN: 2163-8306Frequency: 12 issues/year

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.

THERAPEUTIC DRUG MONITORING

Optimizing Patient Care Through Precision Monitoring
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0163-4356Frequency: 6 issues/year

THERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Bridging Pharmacokinetics and Pharmacodynamics
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 1567-567XFrequency: 6 issues/year

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.

CTS-Clinical and Translational Science

Driving innovation at the intersection of science and medicine.
Publisher: WILEYISSN: 1752-8054Frequency: 12 issues/year

CTS-Clinical and Translational Science, published by WILEY, is a leading journal dedicated to advancing the fields of biochemistry, genetics, molecular biology, medicine, neuroscience, and pharmacology. With its Open Access policy since 2016, the journal ensures that groundbreaking research is readily available to a global audience, fostering collaboration and innovation. Based in the United Kingdom, CTS boasts a commendable Impact Factor that reflects its esteemed status, ranking in the Q1 category for various disciplines, including Pharmacology, Toxicology, and Pharmaceutics, and Biochemistry, Genetics and Molecular Biology. With its convergence years from 2008 to 2024, the journal remains at the forefront of scientific discovery, actively promoting novel research that bridges the gap between laboratory results and clinical application. Researchers, professionals, and students alike will find CTS an invaluable resource for the latest insights and advancements in clinical and translational science.

ANTI-CANCER DRUGS

Unveiling Breakthroughs in Cancer Therapeutics
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

TRENDS IN PHARMACOLOGICAL SCIENCES

Navigating Innovations in Pharmacology and Toxicology
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Exploring the future of drug therapy and pharmacokinetics.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.